J Korean Med Sci.  2023 Mar;38(11):e87. 10.3346/jkms.2023.38.e87.

Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study

• Kim YY
• Choe YJ
• Kim J
• Kim RK
• Jang EJ
• Lee H
• Yi S
• Lee S
• Park YJ

• KMID: 2540653
• DOI: http://doi.org/10.3346/jkms.2023.38.e87

Abstract

National cohort data collected during the coronavirus disease 2019 (COVID-19) delta and omicron periods in Korea revealed a lower risk of severe infection in recipients of three doses of the COVID-19 vaccine (adjusted odds ratio [aOR], 0.05–0.08). The risk of death was reduced during the omicron period compared to the delta period (aOR, 0.75; 95% confidence interval, 0.67–0.84).

Keyword

Coronavirus; COVID-19; SARS-CoV-2; Vaccine; Booster

Figure

• 

  Fig. 1 Multivariable logistic regression model with the composite of sex, age categories, area of residence, month of diagnosis, and vaccination status to estimate risk factors for severe disease and death in patients with PCR-confirmed COVID-19 in South Korea, July 2021–January 2022.PCR = polymerase chain reaction, COVID-19 = coronavirus disease 2019, CI = confidence interval.

Reference

1. Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2-what do they mean? JAMA. 2021; 325(6):529–531. PMID: 33404586.

2. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022; 399(10323):437–446. PMID: 35065011.

3. Choe YJ, Yi S, Hwang I, Kim J, Park YJ, Cho E, et al. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. 2022; 40(5):691–694. PMID: 35012777.

4. Kim EY, Choe YJ, Park H, Jeong H, Chung JH, Yu J, et al. Community transmission of SARS-CoV-2 Omicron variant, South Korea, 2021. Emerg Infect Dis. 2022; 28(4):898–900. PMID: 35171760.

5. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303–1312. PMID: 35305296.

6. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. JAMA. 2022; 327(13):1286–1288. PMID: 35175280.

7. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from Omicron, Delta, and Alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMID: 35264324.

8. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022; 27(9):2200121. PMID: 35241215.

9. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022; 386(19):1804–1816. PMID: 35263534.